YFQLXB-UC01

YFQLXB-UC01 is an investigational cell therapy developed by Shandong Qilu Cell Therapy Engineering Technology for the treatment of decompensated cirrhosis. While specific details on the cell type are not explicitly stated in the registry, the 'UC' designation in Chinese cell therapy nomenclature typically refers to umbilical cord-derived cells, most commonly umbilical cord-derived mesenchymal stem cells (UC-MSCs). The therapy is administered via intravenous infusion and is intended to improve liver function and reduce complications in patients with advanced cirrhosis through potential immunomodulatory and regenerative mechanisms. It is currently being evaluated in a Phase 1/2 clinical trial in China to determine its safety, tolerability, and preliminary efficacy.